Antibody Responses against Pneumocystis jirovecii in Health Care Workers Over Time
Serena Fong , Kieran R. Daly, Renuka Tipirneni, Leah G. Jarlsberg, Kpandja Djawe, Judy V. Koch, Alexandra Swartzman, Brenna Roth, Peter D. Walzer, and Laurence Huang
Author affiliations: San Francisco General Hospital/University of California, San Francisco, San Francisco, California, USA (S. Fong, R. Tipirneni, L.G. Jarlsberg, A. Swartzman, B. Roth, L. Huang); Veterans Affairs Medical Center/University of Cincinnati, Cincinnati, Ohio, USA (K.R. Daly, K. Djawe, J.V. Koch, P.D. Walzer)
Figure 1. . . Differences in antibody levels against Msg at exposure to Pneumocystis jirovecii pneumonia (PCP) or baseline and 3 and 6 months later within groups of health care workers exposed and never exposed to PCP, San Francisco General Hospital, San Francisco, California, USA, 2007–2009. A) MsgA. B) MsgB. C) MsgC1. D) MsgC3. E) MsgC8. F) MsgC9. Msg, major surface glycoprotein.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.